Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006)
- 주제(키워드) Breast neoplasms , Letrozole , Postmenopause , Receptors , estrogen
- 주제(기타) Oncology
- 설명문(일반) [Ahn, Sung Gwe; Jeong, Joon] Gangnam Severance Hosp, Dept Surg, 211 Eonju Ro, Seoul 06273, South Korea; [Nam, Seok Jin] Samsung Med Ctr, Dept Surg, Seoul, South Korea; [Ahn, Sei Hyun] Asan Med Ctr, Dept Surg, Seoul, South Korea; [Jung, Yongsik] Ajou Univ, Dept Surg, Sch Med, Suwon, South Korea; [Park, Heung Kyu] Gachon Univ, Dept Surg, Gil Hosp, Incheon, South Korea; [Lee, Soo Jung] Yeungnam Univ, Dept Surg, Coll Med, Daegu, South Korea; [Kang, Sung Soo] CHA Univ, Dept Surg, Ilsan Med Ctr, Goyang, South Korea; [Han, Wonshik] Seoul Natl Univ, Dept Surg, Coll Med, Seoul, South Korea; [Park, Kyong Hwa] Korea Univ, Dept Internal Med, Div Oncol Hematol, Coll Med, Seoul, South Korea; [Park, Yong Lai] Kangbuk Samsung Hosp, Dept Surg, Seoul, South Korea; [Lee, Jihyoun] Soonchunhyang Univ, Dept Surg, Seoul Hosp, Seoul, South Korea; [Youn, Hyun Jo] Jeonbuk Natl Univ, Dept Surg, Med Sch, Jeonju, South Korea; [Kim, Jun Hyun] Busan St Marys Hosp, Dept Surg, Busan, South Korea; [Yoo, Youngbum] Konkuk Univ, Dept Surg, Med Ctr, Choongju, South Korea; [Song, Jeong Yoon] Kyung Hee Univ Hosp, Dept Surg, Seoul, South Korea; [Ko, Byung Kyun] Ulsan Univ Hosp, Dept Surg, Ulsan, South Korea; [Gwak, Geumhee] Inje Univ, Dept Surg, Sanggye Paik Hosp, Seoul, South Korea; [Chung, Min Sung] Hanyang Univ Hosp, Dept Surg, Seoul, South Korea; [Kim, Sung Yong] Soonchunhyang Univ, Dept Surg, Cheonan Hosp, Cheonan, South Korea; [Cho, Seo Heon] Dong A Univ Hosp, Dept Surg, Busan, South Korea; [Kim, Doyil] Kangseo MizMedi Hosp, Dept Surg, Seoul, South Korea; [Chang, Myung Chul] Dankook Univ Hosp, Dept Surg, Cheonan, South Korea; [Moon, Byung In] Ewha Womans Univ, Dept Surg, Mokdong Hosp, Seoul, South Korea; [Kim, Lee Su] Hallym Univ, Dept Surg, Sacred Heart Hosp, Anyang, South Korea; [Kim, Sei Joong] Gangseo Mizmedi Hosp, Dept Surg, Seoul, South Korea; [Park, Min Ho] Chonnam Natl Univ, Dept Surg, Med Sch, Gwangju, South Korea; [Kim, Tae Hyun] Inje Univ, Dept Surg, Busan Paik Hosp, Busan, South Korea; [Cho, Jihyoung] Keimyung Univ, Dept Surg, Sch Med, Daegu, South Korea; [Lim, Cheol Wan] Soonchunhyang Univ, Dept Surg, Bucheon Hosp, Bucheon, South Korea; [Bae, Young Tae] Pusan Natl Univ Hosp, Dept Surg, Busan, South Korea; [Gong, Gyungyub] Asan Med Ctr, Dept Pathol, Seoul, South Korea; [Bae, Young Kyung] Yeungnam Univ, Dept Pathol, Coll Med, Daegu, South Korea; [Lee, Ahwon] Catholic Univ Korea, Dept Pathol, Seoul St Marys Hosp, Seoul, South Korea
- 등재 SCIE, SCOPUS, KCI등재
- 발행기관 KOREAN BREAST CANCER SOC
- 발행년도 2021
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000181574
- 본문언어 영어
- Published As http://dx.doi.org/10.4048/jbc.2021.24.e17
초록/요약
Purpose: In this trial, we investigated the efficacy and safety of adjuvant letrozole for hormone receptor (HR)-positive breast cancer. Here, we report the clinical outcome in postmenopausal women with HR-positive breast cancer treated with adjuvant letrozole according to estrogen receptor (ER) expression levels. Methods: In this multi-institutional, open-label, observational study, postmenopausal patients with HR-positive breast cancer received adjuvant letrozole (2.5 mg/daily) for 5 years unless they experienced disease progression or unacceptable toxicity or withdrew their consent. The patients were stratified into the following 3 groups according to ER expression levels using a modified Allred score (AS): low, intermediate, and high (AS 3-4, 5-6, and 7-8, respectively). ER expression was centrally reviewed. The primary objective was the 5-year disease-free survival (DFS) rate. Results: Between April 25, 2010, and February 5, 2014, 440 patients were enrolled. With a median follow-up of 62.0 months, the 5-year DFS rate in all patients was 94.2% (95% confidence interval [CI], 91.8-96.6). The 5-year DFS and recurrence-free survival (RFS) rates did not differ according to ER expression; the 5-year DFS rates were 94.3% and 94.1%in the low-to-intermediate and high expression groups, respectively (p = 0.6), and the corresponding 5-year RFS rates were 95.7% and 95.4%, respectively (p = 0.7). Furthermore, 25 patients discontinued letrozole because of drug toxicity. Conclusion: Treatment with adjuvant letrozole showed very favorable treatment outcomes and good tolerability among Korean postmenopausal women with ER-positive breast cancer, independent of ER expression.
more